C4 Therapeutics sets cemsidomide trial timelines through 2028

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. VRNS
2. CRWV
3. TSLA
4. JBHT
5. GPRK
6. SCHW
7. TRV
8. TFC
9. SPY
10. AA

Go back to C4 Therapeutics sets cemsidomide trial timelines through 2028

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

January 14, 2026 7:00 AM EST

 Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg

Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026

Internal Discovery Strategy Progressing Efforts Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases With Novel Targets in Clinically Validated Pathways

Cash Runway to End of 2028 Provides Funding Through Key Value Inflection Points

WATERTOWN, Mass., Jan. 14, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein... More